Cerenome (PSTV) Net Cash Flow (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Net Cash Flow of -$5.7 million for Q1 2026, down 158.58% year-over-year from $9.8 million in Q1 2025, and down 26.09% quarter-over-quarter from -$4.5 million in Q4 2025.
Cerenome (PSTV) Net Cash Flow (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Net Cash Flow for 17 consecutive years, with -$5.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 158.58% year-over-year to -$5.7 million; the TTM figure through Mar 2026 stood at -$6.8 million (down 198.26% YoY), while the FY2025 annual figure was $8.7 million, up 202.41% from the prior year.
- Net Cash Flow declined to -$5.7 million in Q1 2026 per PSTV's latest filing, from -$4.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $11.1 million in Q3 2025 and bottomed at -$7.6 million in Q2 2025.
- Historically, Net Cash Flow has averaged -$904588.2 across 5 years, with a median of -$2.1 million in 2022.
- Annual changes were most pronounced in 2024 — Net Cash Flow sank 3423.42% — and 2025, when it surged 400.19%.
- Plus Therapeutics' Net Cash Flow stood at -$2.1 million in 2022, then retreated by 14.26% to -$2.5 million in 2023, then surged by 53.22% to -$1.1 million in 2024, then sank by 296.6% to -$4.5 million in 2025, then decreased by 26.09% to -$5.7 million in 2026.
- Business Quant data shows PSTV's Net Cash Flow at -$5.7 million in Q1 2026, -$4.5 million in Q4 2025, and $11.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | -656,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.74 Mn |
| Mar 31, 2026 | -5.74 Mn |
| Dec 31, 2025 | -4.55 Mn |
| Dec 31, 2025 | -4.55 Mn |
| Sep 30, 2025 | 11.07 Mn |
| Sep 30, 2025 | 11.07 Mn |
| Jun 30, 2025 | -7.63 Mn |
| Jun 30, 2025 | -7.63 Mn |
| Mar 31, 2025 | 9.79 Mn |
| Mar 31, 2025 | 9.79 Mn |
| Dec 31, 2024 | -1.15 Mn |
| Dec 31, 2024 | -1.15 Mn |
| Sep 30, 2024 | -3.69 Mn |
| Sep 30, 2024 | -3.69 Mn |
| Jun 30, 2024 | 2.01 Mn |
| Jun 30, 2024 | 2.01 Mn |
| Mar 31, 2024 | -5.65 Mn |
| Mar 31, 2024 | -5.65 Mn |
| Dec 31, 2023 | -2.45 Mn |
| Dec 31, 2023 | -2.45 Mn |